The Düsseldorf e-commerce group The Platform Group AG announced further acquisition on Thursday and raised its medium-term forecasts.
The group announces further takeover in the areas of Pharma and Optics & Hearing
The group of companies said that it will acquire majority investments to three other companies from the pharmaceutical sector. This is the Pharmosan Group based in Vienna, the Czech mail order pharmacy Vamida and Pharmacy, a further training platform for the pharmaceutical industry based in Cologne. The transactions that still require the approval of the responsible antitrust authorities are to be carried out by the end of the year.
The joint sales volume of the three companies in 2026 quantified The Platform Group at more than 130 million euros. In the course of the acquisitions, the group segment “Service & Retail Goods” will be expanded and “in the future under the name ‘Pharma & Service Goods’,” says a message. The group of companies also “made agreements on the acquisition of two other companies in the ‘Optics & Hearing’ segment.”
Management increases its sales and profit forecasts for 2026
Chief Financial Officer (CFO) Bjoern Minnier commented on the recent growth steps: “The takeovers in the pharmaceutical area and in the optics & hearing segment show that we successfully expand our niche strategy. This will further develop the profitability of our group,” he said in a statement.
In view of the new additions, management set higher medium -term goals. A net turnover of around 1.0 billion euros is now forecast for the 2026 financial year. So far, 860 million euros had been expected. The goal of the gross -like volume (GMV), which had so far been 1.6 billion euros, increased to 1.7 billion euros. The forecast for the adjusted result before interest, taxes and depreciation (EBITDA) in 2026 was raised from 68 million euros to 70 to 80 million euros. The forecasts for the current financial year 2025 remained unchanged.